CytoDyn (STU:296) Institutional Ownership : 0.01% (As of Apr. 14, 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytoDyn's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytoDyn's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytoDyn's Float Percentage Of Total Shares Outstanding is 99.83%.

CytoDyn Institutional Ownership Historical Data

The historical data trend for CytoDyn's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Institutional Ownership Chart

CytoDyn Historical Data

The historical data trend for CytoDyn can be seen below:

	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31
Institutional Ownership	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

CytoDyn Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

CytoDyn Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CYDY:USA

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines